25.04.2021, 5367 Zeichen

Immofinanz: Reals Estate company Immofinan recorded an increase in rental income and results of property sales in 2020 despite the Covid-19 crisis. Rental income rose by 3.1% to Euro 288.6 mn due to the strong growth in the portfolio during the second half of 2019, but a crisis-related increase in receivables write-offs from asset management led to substantially higher property expenses. The results of asset management totalled Euro 206.4 mn in 2020 and reflect the previous year despite these write-offs. The pandemic also had a negative influence on the valuation of investment property: revaluations totalled Euro -166.5 mn, compared with clearly positive results in the previous year (2019: Euro 193.3 mn). This reduction represents roughly 3.2% of the total property portfolio. In addition, the continuing decline in the price of the S IMMO share during 2020 led to a write-down of Euro -88.6 mn in this investment to Euro 363.6 mn. Net loss for the 2020 financial year amounted to Euro -165.9 mn (2019: + 352.1 mn). In view of the Group’s solid capital base, the Executive Board will make a recommendation to the 28th annual general meeting on 18 June 2021 to distribute a dividend of Euro 0.55 per share.
Immofinanz: weekly performance: 0.00%

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that Carragelose inactivates the new, rapidly spreading variants and SARS-CoV-2 wildtype with similar efficacy in vitro. The Company tested the three variants that currently mostly drive the COVID-19 pandemic, namely the so-called British or B.1.1.7, the South-African or B.1.351, and the Brazilian or P1 variant.The data demonstrate that also with increasing prevalence of virus variants, the marketed OTC Carragelose-based lozenges, nasal and throat sprays will continue to effectively contribute to combatting the COVID-19 pandemic. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. “Given the broad antiviral efficacy and the physical mode of action, we were convinced that SARS‑CoV‑2 variants are unlikely to evade the antiviral efficacy of Carragelose. With these new results we confirmed the hypothesis that our Carragelose-based products continue to be effective also against the mutations of concern currently emerging strongly. We believe that this will hold true for any future variants.”
Marinomed Biotech: weekly performance: 1.82%

Valneva: Valneva, an Austrian/French specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced it is now focusing on bilateral discussions, on a country by country basis, to supply its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, and is consequently deprioritizing the ongoing centralized discussions with the European Commission (EC). CEO Thomas Lingelbach: “We’ve committed significant time and effort to try to meet the needs of the central EC procurement process. Despite our recent clinical data, we have not made meaningful progress and have not yet secured a supply agreement. We are therefore now focusing our efforts on those European Union member states, and interested parties outside the EU, who would like to include our inactivated approach within their vaccination strategy. We are convinced that VLA2001 has an important role to play in the future, including boosters or potential modifications to the vaccine to address variants.”
Valneva: weekly performance: -9.05%

FACC: With PURE CABIN, the internationally leading aerospace company FACC has created an innovative, antimicrobial surface coating for aircraft cabins. In addition to strengthening the technology group's position in the important field of aftermarket services, PURE CABIN offers passengers a relaxed and carefree flight experience in compliance with the highest safety standards. FACC will present the innovation to the market at MRO Americas taking place end April in Orlando, USA.
FACC: weekly performance: -0.22%

AT&S: AT&S, Austrian based manufacturer of high-end printed circuit boards (PCB), uses “smart” quality controls in its PCB production. The Know-Center developed an AI algorithm for AT&S, which not only correctly recognizes the images of the circuit boards, but also provides an explanation of why a circuit board has been recognized as defective or intact. As a result, AT&S now has a transparent AI system at its disposal, which, after an intensive test phase, should deliver comprehensible and explainable results in the near future.
AT&S: weekly performance: -3.86%

Lenzing: Fibers producer Lenzing Group got off to a better-than-expected start to the financial year 2021, with preliminary EBITDA (earnings before interest, tax, depreciation and amortization) rising by 36.8 percent year-on-year to Euro 94.5 mn in the first quarter of 2021.Despite the continuing high degree of volatility in the textile sector due to the COVID-19 pandemic, the Managing Board of the Lenzing Group raises its guidance for the 2021 financial year: The Lenzing Group expects the operating result to be at least at the level of the pre-crisis year 2019.
Lenzing: weekly performance: -1.79%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (21/04/2021)

Christian Drastil: Wiener Börse Plausch

Zertifikate Party Österreich 12/24: Diesmal kurze Party, 2025 startet dafür unser Real-Money-Zertifikate-Depot mit 14tägigen Podcasts

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, Warimpex, RHI Magnesita, Immofinanz, Addiko Bank, CA Immo, Mayr-Melnhof, Verbund, ATX, ATX Prime, ATX TR, Wienerberger, Kostad, EVN, Lenzing, Österreichische Post, Strabag, Athos Immobilien, AT&S, Cleen Energy, Marinomed Biotech, RWT AG, SBO, UBM, Agrana, Amag, Flughafen Wien, OMV, Palfinger, Telekom Austria, Uniqa.

---